Insider Selling: Oncomed Pharmaceuticals SVP Sells 1,500 Shares of Stock (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) SVP Jakob Dupont sold 1,500 shares of the stock on the open market in a transaction dated Thursday, June 26th. The stock was sold at an average price of $23.00, for a total transaction of $34,500.00. Following the completion of the sale, the senior vice president now directly owns 20,896 shares of the company’s stock, valued at approximately $480,608. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. Separately, analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.10 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $37.78.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 4.44% on Monday, hitting $23.30. The stock had a trading volume of 145,391 shares. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock has a 50-day moving average of $23.26 and a 200-day moving average of $29.06. The company’s market cap is $688.6 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last released its earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.34. On average, analysts predict that Oncomed Pharmaceuticals will post $-0.76 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.